Pharma Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Ciphergen Biosystems
Ciphergen reports positive results from multicenter validation ovarian cancer biomarker study
July 4th, 2006
Ciphergen Biosystems, Inc. (CIPH) announced results of a multicenter study evaluating the performance of a set of seven biomarkers for the detection of ovarian cancer. Six hundred seven (607) patient samples taken from five international medical centers were evaluated for each of the seven markers. Two hundred thirty four (234) women had benign gynecologic disease and 373 patients had invasive epithelial ovarian cancer, including 101 with early stage cancer. All seven biomarkers individually demonstrated statistically significant power to differentiate ovarian cancer patients from women with benign disease, and most biomarkers had p<.00001. As in...
Source: Pharma Law Weekly (2006-07-04)
|
